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Abstract
Background: Erosive lichen planus affecting the vulva (ELPV) is a relatively rare, chronic condition causing painful
raw areas in the vulvovaginal region. Symptoms are pain and burning, which impact upon daily living. There is
paucity of evidence regarding therapy. A 2012 Cochrane systematic review found no randomised controlled trials
(RCTs) in this field. Topically administered corticosteroids are the accepted first-line therapy: however, there is
uncertainty as to which second-line treatments to use. Several systemic agents have been clinically noted to show
promise for ELPV refractory to topically administered corticosteroids but there is no RCT evidence to support these.
The ‘hELP’ study is a RCT with an internal pilot phase designed to provide high-quality evidence.
Methods/Design: The objective is to test whether systemic therapy in addition to standard topical therapy is a
beneficial second-line treatment for ELPV. Adjunctive systemic therapies used are hydroxychloroquine, methotrexate,
mycophenolate mofetil and prednisolone. Topical therapy plus a short course of prednisolone given orally is
considered the comparator intervention. The trial is a four-armed, open-label, pragmatic RCT which uses a blinded
independent clinical assessor. To provide 80 % power for each comparison, 96 participants are required in total. The
pilot phase aims to recruit 40 participants.
The primary clinical outcome is the proportion of patients achieving treatment success at 6 months. ‘Success’ is
defined by a composite measure of Patient Global Assessment score of 0 or 1 on a 4-point scale plus improvement
from baseline on clinical photographs scored by a clinician blinded to treatment allocation. Secondary clinical
outcomes include 6-month assessment of: (1) Reduction in pain/soreness; (2) Global assessment of disease; (3)
Response at other affected mucosal sites; (4) Hospital Anxiety and Depression Scale scores; (5) Sexual function; (6)
Health-related quality of life using ‘Short Form 36’ and ‘Skindex-29’ questionnaires; (7) Days of topical steroid use; (8)
Treatment satisfaction; (9) Discontinuation of medications due to treatment failure; (10) Per participant cost of
intervention in each treatment group. Adverse events will also be reported.
Discussion: ‘hELP’ is the first RCT to address second-line treatment of ELPV. The trial has encountered unique
methodological challenges and has required collaborative efforts of the UK Dermatology Clinical Trials Network
alongside expert clinicians.
Trial registration: current controlled trials: ISRCTN 81883379. Date of registration 12 June 2014.
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Background
Erosive lichen planus is a chronic inflammatory, scarring
skin condition that most commonly occurs on the mucosal
surfaces of the mouth and genital region. It is believed to
be an autoimmune condition [1, 2] with T-cell-mediated
damage to keratinocytes in the basal layer of the epidermis
[3], although the exact pathogenesis remains unclear.
Erosive lichen planus affecting the vulvovaginal region
(ELPV) causes painful raw areas at the vaginal entrance,
and subsequent scarring leads to anatomical changes
with narrowing of the vaginal canal. Symptoms can pre-
vent normal daily activities such as walking/sitting,
washing, going to the toilet and normal sexual function.
Additionally, there is a 1–3 % risk of cancerous change
in affected skin although the timescale for malignancy to
occur is unclear [4–6].
ELPV is estimated to affect 0.01 % of women. However,
this is likely an underestimate with many cases failing to
present to medical services [7].
No robust, high-quality randomised controlled trials
(RCTs) have been published on which to base treatment
decisions for ELPV [8]. First-line therapy is typically with
the super-potent topical steroid clobetasol propionate
0.05 % [9, 10]. Non-randomised studies, mainly retro-
spective case series, have suggested that clobetasol pro-
pionate is an appropriate first-line therapy [6, 11–13].
However, in the only prospectively-collected case series
[6], one third of patients responded poorly to this type
of treatment.
There is currently no agreement as to which second-
line agents should be used [10, 14]. Therapeutic choice
is based upon expert opinion and predominantly
includes immunosuppressant or immune-modifying
agents.
Expert clinicians anecdotally believe that systemic
treatments with the greatest success rates are hydroxy-
chloroquine, methotrexate, mycophenolate mofetil and
prednisolone. In a UK-based multi-centre case note re-
view of 172 patients, these were the most commonly
prescribed systemic agents [9]. However, there are insuf-
ficient data within the medical literature to make an
evidence-based decision on the most effective. The
‘hELP’ trial (Systemic therapy for vulval Erosive Lichen
Planus) has been designed to test all four of the more
common interventions in one four-armed RCT with an
internal pilot.
The objectives of the ‘hELP’ study are to administer,
for a 6-month period, in patients with ELPV that has
been refractory to first-line therapy, clobetasol propion-
ate 0.05 % topically plus adjuvant systemic therapy with
hydroxychloroquine, methotrexate or mycophenolate
mofetil, and compare against topically administered clo-
betasol propionate 0.05 % with adjuvant prednisolone
given orally.
Methods/Design
Study design
The ‘hELP’ trial is a multi-centre, four-armed, open-label
pragmatic RCT. The trial has a 12-month internal pilot
phase. Participants are being recruited from 12 hospitals
throughout the UK which hold specialist vulval clinics.
The active intervention phase is for 6 months after which
the primary outcome will be assessed. Participants will be
followed up for 12 months after randomisation. Treatment
regimens and monitoring are based upon national guidance
issued by the British Association of Dermatologists [15].
Study visits mimic the schedule of clinic appointments seen
in usual clinical practice, the timings of which were set
following consultation with expert clinicians.
Participants
Inclusion criteria are
i). Aged 18 or over;
ii). Clinical diagnosis of moderate to severe ELPV,
despite first-line therapy for 3 months with clobeta-
sol propionate 0.05 %;
iii).A documented vulval biopsy at some point in their
history to exclude malignant/pre-malignant disease.
The biopsy should be repeated if clinical features
have changed or are suspicious;
iv).Willing to have clinical photographs taken;
v). If of childbearing potential, willing to use effective
contraceptive methods whilst taking systemic
therapy (and in the case of methotrexate for
6 months after the end of treatment);
vi).Willing to give informed consent.
Participants are ineligible if they have:
i). Lichen sclerosus/lichen planus overlap syndrome;
ii). Received one or more of the trial drugs within the
last month (excluding topical therapy);
iii).A previous or current diagnosis of malignant
disease;
iv).Pre-malignant cervical or vulval disease;
v). Received a live vaccine in the 2 weeks before
starting trial treatment;
vi).Pregnancy or are breast-feeding;
vii).Known allergy to any of the trial medications;
viii).Previous history of clinically significant renal or liver
impairment, or concurrent medications that would
interact with the trial drugs;
ix).Any other reason that the trial drugs would not be
given in usual clinical practice.
Interventions
All participants receive standard topical therapy of clo-
betasol propionate 0.05 % once daily for 1 month and
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the regimen will be reduced according to response
thereafter. If the condition worsens, application may be
increased, but as ELPV is a relapsing remitting condition,
this does not necessarily indicate treatment failure. A
maximum of 60 g clobetasol propionate 0.05 % over
6 months should be used.
Participants will be randomised to receive one of four
systemic treatments (in addition to topical therapy)
for a period of 6 months. The 4-week course of prednisol-
one given orally will be considered the comparator
intervention.
Topical therapy alone would have been a simpler com-
parator, but we considered it unethical to continue this
alone as, by definition to enter the trial, topical therapy
must have failed. Therefore, a short course of prednisol-
one given orally for the first month is given to the com-
parator group.
Intervention regimens
1. Prednisolone given orally starting at 20 mg once
daily for 1 week, reducing by 5 mg per week for
4 weeks. Where clinically indicated, gastric and bone
protection should be prescribed according to usual
practice.
2. Oral hydroxychloroquine tablets up to 6.5 mg/kg
body weight with a maximum dose of 200 mg twice
daily.
3. Oral methotrexate tablets commencing at 5 mg/
week and gradually titrated according to response to
a maximum of 25 mg/week.
4. Oral mycophenolate mofetil tablets commencing at
500 mg once daily and gradually titrated according
to response to a maximum dose of 1.5 g twice daily.
Treating clinicians are advised to titrate the dose of
the active interventions, according to response and toler-
ability, as detailed in national guidelines issued by the
British Association of Dermatologists [15]. As metho-
trexate is a folate antagonist it is recommended that par-
ticipants are prescribed adjunctive folic acid 5 mg daily
except on the day of methotrexate administration. Clini-
cians are allowed to use their clinical judgement to deviate
from these recommendations if clinically necessary.
Participants in the RCT should not use any other top-
ical or systemic treatments for ELPV after randomisa-
tion. There is a 4-week washout period of any pre-
existing therapy with the exception of clobetasol propi-
onate 0.05 %. All other concomitant medications should
continue as per normal care. The use of live vaccines is
not permitted during the intervention phase of the trial
and the prescription of any additional medications for
ELPV during the trial period is considered as a treat-
ment failure.
Outcomes
Feasibility outcomes
After the end of the internal pilot phase feasibility out-
comes will be reported:
The feasibility primary outcome is to establish the pro-
portion of eligible patients willing to be randomised to
systemic treatment.
The feasibility secondary outcomes are:
i). To establish participants’ adherence to treatment
regimens;
ii). To assess the quality of photographs obtained and
suitability for blinded clinical assessment of disease
severity;
iii).To assess the suitability and completion of paper-
based case report forms;
iv).To trial a four-armed study design in this population
and assess what implications using multiple arms has
on recruitment and overall study conduct including
post-randomisation dropouts;
v). To evaluate the suitability of the chosen clinical
outcomes for evaluating treatment response in ELPV.
Clinical outcomes
Primary clinical outcome measure
The primary outcome of the ‘hELP’ study is the propor-
tion of patients achieving treatment success at 6 months.
Treatment will be classed as successful if both patient
and investigator success criteria are met:
 Patient Global Assessment of disease severity of
‘none’ or ‘mild’ (on a 4-point scale of none, mild,
moderate or severe disease)
 Any improvement from baseline judged by blinded
assessment of clinical photographs
The composite outcome incorporates both blinded as-
sessment of physical signs, where blinding is important
in open-label trials, and patient assessment of symptoms,
which is important because physical signs do not always
reflect symptoms.
Secondary clinical outcome measures
Secondary outcomes comprise the following:
i). Reduction in soreness from baseline at 6 months
assessed using a 10-point score (0 = no soreness, 10
=most soreness);
ii). Disease severity assessed individually by: a) Patient
Global Assessment at baseline, 3, 6 and 12 months,
b) Investigator assessment by treating clinician at
baseline, 3 and 6 months, c) Investigator assessment
by blinded assessor using clinical images at baseline
and 6 months;
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iii).Investigator assessment of severity of oral and
vaginal sites if affected at baseline, 3 and 6 months;
iv).Psychological assessment using the Hospital Anxiety
and Depression Scale at baseline and 6 months;
v). Sexual function questionnaire at baseline 6 and
12 months;
vi).Health-related quality of life using ‘Skindex-29’ and
‘Short Form 36’ questionnaires at baseline and
6 months;
vii).Days of topical steroid use (as a marker of disease
control in each of the groups);
viii).Overall treatment satisfaction;
ix).Economic evaluation, which will calculate the
average cost of intervention in each treatment group
per participant based on prescribed medication.
Participant timelines
Informed consent will be obtained by the recruiting clin-
ician prior to conducting any trial-specific procedures.
Eligible, consented participants will have baseline symp-
toms and signs recorded, including a digital photograph.
A thorough medical history will be taken to ensure their
suitability to receive any of the trial medications. Partici-
pants will subsequently be randomised to one of the four
trial arms, following which medication-specific eligibility
assessments will be conducted (e.g. X-rays for the
methotrexate group). Treatment will start once the re-
sults of these tests are known to be satisfactory. Stand-
ard safety monitoring will be conducted as per national
guidance [15] and in accordance with the individual
Summary of Medical Product Characteristics.
Follow-up visits will be at 1, 3 and 6 months to review
safety monitoring investigation results, check adherence,
titrate medication dosage if required and record out-
come measure parameters. Women of childbearing po-
tential who are sexually active will have pregnancy
testing carried out and the importance of effective
contraception reiterated. The primary outcome is
assessed after 6 months of therapy, although primary
and secondary endpoint data are collected at both 3-
and 6-month visits (Fig. 1).
After the 6-month visit normal care will resume; the
trial medication will continue if adequate control has
been achieved, otherwise an alternative approach will be
chosen by the treating clinician. No further in-person
trial visits will be required: however, participants will be
contacted by phone or Email at 12 months by the coord-
inating centre to assess long-term outcomes.
Data collection
With the exception of clinical photographs, data are col-
lected through paper-based Case Report Forms (CRFs)
and participant diaries. Assessors are trained during site
initiation visits on how to complete the CRFs accurately.
Clinical photographs are obtained digitally through the
site’s local medical illustration department. A photo-
graphic protocol is available to ensure standardisation of
image quality. Although medical illustration is the pre-
ferred method of photography, if not available at site, cli-
nicians may take the photographs in line with the
photographic protocol. It is mandatory that the same
method of photography (i.e. medical illustration or clin-
ician) is used for the two time points for an individual
patient to ensure comparability of images.
Photographs and CRFs are confidential documents
and are held securely. Each participant will be assigned a
trial identity code number so that documented data are
non-identifiable. Any personal information will be stored
on a password protected, secure server and will only be
looked at by authorised individuals from the University
of Nottingham, the research group, and regulatory au-
thorities where relevant.
A summary of assessments performed at the different
time points is demonstrated in Table 1.
Sample size and recruitment
Each treatment group will be compared with the com-
parator group on the primary outcome with adjustment
for multiple testing. Assuming a comparator arm success
rate (primary outcome measure) of 10 % at 6 months
and using a 1:1:1:1 allocation ratio, 96 participants will
be required to detect a 40 % absolute increase in the
proportion of successes to 50 %, with 80 % power and
maintaining the 2-sided familywise error rate at 5 % [16].
As there is very little evidence on which to base treatment
effect size, feedback from clinicians and patients was that
a substantial improvement would be necessary in order to
justify systemic treatment to treat the condition.
The internal pilot recruitment period will be 12 months
during which we aim to recruit 40 participants. If fewer
than 40 participants are recruited, recruitment will stop
and feasibility outcomes will be reported.
Randomisation and blinding
Randomisation codes have been generated by computer
using minimization using the Taves minimisation method
[17], with an 80 % chance to minimise (VBScript within
an ASP web application), and are held by the Nottingham
Clinical Trials Unit. Randomisation is based on the mini-
misation criteria of recruiting centre and baseline disease
severity. Participants who are found to be ineligible fol-
lowing medication-specific pre-treatment investigations
will be removed from the trial and not replaced.
The randomisation sequence will be concealed until re-
cruitment, data collection, and data cleaning are complete.
This is an assessor-blind study with part of the pri-
mary outcome measure (clinical assessment of disease
improvement) being judged on the basis of anonymised
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and blinded digital photographs. This will protect
against detection bias. Digital photographs will be
assessed by two assessors who are blinded to treatment
allocation. Any discrepancy will be adjudicated by a third
independent assessor. The trial statistician will also be
blinded until the final analysis.
Since the clinician and participants are aware of the
treatment allocation, no special measures are required to
allow for breaking codes. Treatment allocation will be
concealed from the treating clinician until the patient’s
key details and minimisation variables have been entered
into the randomisation system.
Statistical analysis
If fewer than 40 participants in 12 months are recruited,
feasibility outcomes will be reported. Summary data for
efficacy outcomes will still be reported in full for poten-
tial inclusion in future meta-analyses. However, signifi-
cance testing and multiple imputation of missing data
will not be considered.
All analyses will be performed using the intention-to-
treat principle. The ‘Full Analysis Set’ will be all partici-
pants who are randomised and continue to be eligible
after the post-randomisation eligibility assessments to
their allocated trial arm regardless of whether they com-
mence the study medication, or not. All primary and
secondary outcome measures will be analysed using this
sample of patients.
The primary clinical outcome measure will also be
assessed on a per-protocol sample which includes all
participants in the ‘Full Analysis Set’ who are deemed to
have no major protocol violations that could interfere
Fig. 1 Systemic therapy for vulval Erosive Lichen Planus (‘hELP’) study flow diagram. Internal pilot phase to run for 12 months, after which recruitment
rates will be assessed and a decision made whether or not to continue onto a definitive trial
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with the objectives of the study: for example, continuing
concomitant medications that are contraindicated in
conjunction with the trial treatments.
The primary clinical outcome is a composite measure
comprising assessment of digital photographs and Pa-
tient Global Assessment. If digital photographs are not
available for any of the participants, the assessment that
has been recorded by the treating clinician as part of
data collection at each trial visit will be used instead.
However, if used, this assessment will be unblinded due
to the open-label nature of the trial.
Multiple imputation will be used to deal with missing
patient assessments or investigator assessments. Fifty
imputations will be used to generate 50 complete data-
sets. The relevant outcome in each dataset will be ana-
lysed using the corresponding methods described above
with the results across datasets combined using Rubin’s
rules. Imputations will be done separately within treat-
ment groups.
Statistical tests will be at the 2-sided 0.05 level, apart
from the analysis of the primary clinical outcome meas-
ure, which will adjust for multiple comparisons using
Dunnett’s step-down procedure [18] to control the family-
wise error rate at the 0.05 level. All analyses will be ad-
justed for the minimisation variables and, if applicable, the
baseline measurement of the corresponding outcome.
Treatment effects for binary outcomes (including pri-
mary clinical outcome) will be analysed using a binomial
regression model with identity link and will be presented
as an absolute difference in proportions.
The change in continuous outcomes between baseline
and follow-up will be compared between treatment arms
using an absolute difference in means, estimated using a
multiple linear regression model.
Table 1 Summary of the Systemic therapy for vulval Erosive Lichen Planus (‘hELP’) trial assessments to be made at study visits
Assessment 0 months 1 month 3 months 6 months 12
monthsgScreening/
Eligibility
Baseline/
Randomisation
Start of
treatment
Informed consent ✓
Eligibility checks ✓
Medical history ✓ ✓ ✓
Demographics ✓
Randomisation ✓
Standard safety monitoringa ✓ ✓ ✓ ✓
Pregnancy testb ✓ ✓ ✓ ✓ Check
status
Prescription givenc ✓ ✓ ✓ ✓
Treatment logd ✓ ✓ ✓ ✓
Digital photographse ✓ ✓
Pain/Soreness scoref ✓ ✓ ✓
PGAf ✓ ✓ ✓ ✓
Investigator assessment of vulva ✓ ✓ ✓
Investigator assessment of other affected
sites
✓ ✓ ✓
HADS scoref ✓ ✓
Assessment of sexual functionf ✓ ✓
Skindex-29f ✓ ✓
SF36f ✓ ✓
Patient diaryf ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓
HADS Hospital Anxiety and Depression Scale, PGA Patient Global Assessment, SF36 ‘Short Form 36’
aAs per national guidance
bFor women of childbearing potential who are sexually active
cDoses titrated according to ‘hELP’ study protocol
dRecord any prescriptions given during follow-up visit
ePhotographs ideally to be taken by medical photography (photographs at baseline and 6 months must be by same mode), analysis by blinded assessor at
coordinating centre
fAssessment completed by the participant
gAssessment to be carried out by telephone, letter or Email
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Categorical outcomes will be analysed using ordinal
logistic regression and treatment effects will be presented
using odds ratios. All models will adjust for treatment
allocation and minimisation factors.
Days of topical steroid use will be analysed using a
negative binomial model with the number of days of
follow-up for each patients included in the model as an
offset.
The chief investigator (CI) will maintain responsibility
for final trial dataset and data will be available on
request.
Study organisation and funding
This study is coordinated from the Centre of Evidence
Based Dermatology [19] at the University of Nottingham
with support from the UK Dermatology Clinical Trials
Network [20]. It is funded by the National Institute of
Health Research as part of a Doctoral Research Fellowship
(DRF-2012-05-166). The award holder (RS) is the trial
manager. Additional trial administrative support is pro-
vided by the University of Nottingham. Research nurse
support is provided through the National Institute for
Health Research (NIHR) Clinical Research Networks. The
research is sponsored by the University of Nottingham.
Research ethics approval has been obtained from the
Sheffield NRES Committee – York and The Humber
(reference 14/YH/0046).
The study protocol was developed in accordance with
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) 2013 guidelines (Additional file 1).
The CI has overall responsibility for the study and is
supported by the trial’s medical expert.
The Trial Management Group (TMG), which meets
monthly, includes the CI (KT), medical expert (RM),
trial manager (RS), assistant trial manager (HN), clinical
trials development manager (SD) and trial statistician
(SW). The trial is overseen by a Trial Steering Commit-
tee (TSC), which includes an independent chair and four
other independent members (one of whom is a patient
with ELPV) plus representatives from the TMG. The In-
dependent Data Monitoring Committee (IDMC) consists
of three members. Meetings for the DMC and TSC
occur annually or more frequently if required. All mem-
bers are independent of the study team although the CI
and trial manager (plus other members of the TMG as
necessary) attend open sessions to inform the oversight
committees of trial progress.
Discussion
The ‘hELP’ trial has encountered some unique methodo-
logical challenges due to its pragmatic ethos and the fact
that ELPV is a relatively rare condition. As the study is
funded through a Doctoral Research Fellowship, investi-
gators are contributing on a voluntary basis as they
believe this is a clinically important question that will
help to improve practice, and trial drugs are prescribed
through normal clinical care pathways. This recruitment
model has been successfully used in other UK Dermatol-
ogy Clinical Trials Network Trials [21]. An example of a
study previously developed in this way for a rare skin
condition is the ‘STOP GAP’ trial of prednisolone versus
cyclosporin for pyoderma gangrenosum [22].
The reason for designing an open-label trial is that the
very different treatment regimens, and safety monitoring
requirements for the four systemic therapies, meant that
blinding of participants and clinicians would have been
impractical and would have required each participant to
additionally take multiple placebo tablets. Furthermore,
it was felt that with so many different regimens and the
potential side effects of some of the treatments, it could
have been potentially dangerous to blind the patient and
investigator to the intervention. Nevertheless, measures
were taken to ensure the scientific integrity of the trial,
including randomisation and allocation concealment
through an accredited Clinical Trials Unit, and blinded
outcome assessment using digital images to limit detec-
tion bias.
Due to the fact that the treatment groups require differ-
ent pre-treatment safety assessments, the decision was
made to perform treatment-specific eligibility assessments
postrandomisation. It was considered unethical and im-
practical to perform certain tests prior to randomisation
as some participants would undergo investigations (e.g. X-
rays) that were not required. To minimise the potential
for post-randomisation dropouts, a detailed medical his-
tory is taken and any potential medical issues investigated
prior to inclusion in the study.
This is the first RCT to compare systemic therapies in
ELPV, making the choice of target interventions difficult.
As patient numbers are scarce and resources limited in
this population, it was decided to design a four-arm
study which could give a preliminary indication of which
of the trial interventions is most likely to be effective.
Eligibility criteria were chosen based upon usual clin-
ical practice. In particular, participants must have had a
vulval biopsy at some point in their history. The biopsy
must have excluded malignant or pre-malignant disease.
The procedure is painful and distressing to patients and,
therefore, the study does not require the biopsy to be re-
peated unless clinically suspicious features develop. Biopsy
is not used to diagnose ELPV per se because classic histo-
logical features of disease are not always seen [13, 23]. In
clinical practice, biopsy is used to rule out malignancy/
pre-malignancy, which are in the differential diagnosis of
the condition. This is particularly important if the use of
immunosuppressive medications is planned. It may be
considered that the need to have a documented biopsy as
an inclusion criterion is a source of bias, but, it is a
Simpson et al. Trials  (2016) 17:2 Page 7 of 9
necessary safety precaution and would be considered neg-
ligent practice to use the trial medications without it.
The choice of interventions in the study was devel-
oped in conjunction with collaborating expert clinicians
through the British Society for the Study of Vulval Dis-
ease. Although topical therapy alone as the comparator
may have been the ideal choice, it was considered uneth-
ical to continue this alone as, by definition, to enter the
trial topical therapy must have failed. Therefore, a short
course of prednisolone given orally was added for the
first month to the comparator group. As prednisolone’s
effects are short-lived, disease control at 6-months for
the primary outcome should be the equivalent of using
topical therapy alone in this group.
As systemic therapies can take weeks or months to
produce optimum effect, the rationale for using clobeta-
sol propionate 0.05 % with the investigational adjunctive
systemic therapies is that ELPV may flare severely if top-
ical treatment is stopped abruptly. As the systemic ther-
apies take effect, disease control should improve and
patients should find that they can reduce the frequency
of application of clobetasol propionate 0.05 % without
experiencing flares. If the condition is not controlled by
the systemic agent they can continue to use clobetasol
propionate 0.05 % on a more frequent basis. Therefore,
the frequency of application of clobetasol propionate
0.05 % will act as a marker of disease control achieved
by the systemic agents.
With no validated outcome measures for ELPV the
primary endpoint was considered at length and was
devised following careful discussion with clinicians and
patients. As this is an open-label trial any patient- and
investigator-rated outcomes, except the independent
blinded assessment of the clinical photographs, may be
subject to bias. The Trial Development Group (TDG) felt
it was important to maintain the integrity of the trial by
going to the additional length of a blinded assessor to
score clinical photographs. However, it is important that
patients’ views are also taken into consideration as symp-
toms and impact of disease play a large part in clinicians’
therapeutic decision-making. The decision to use a com-
posite endpoint was, therefore, made. Subjective symp-
toms need to be taken in context with clinical signs:
therefore, improvements in both patient and investigator
assessments are required to classify treatment success.
The ‘hELP’ trial is the first of its kind and, in consult-
ation with clinicians and patients, we have endeavoured
to produce a pragmatic and clinically relevant RCT
within the limited resources available.
Trial status
Recruitment into this trial started in July 2014 and is
taking place in 12 secondary care hospitals in the United
Kingdom. Recruitment ended on 31 July 2015.
Additional files
Additional file 1: SPIRIT checklist_’hELP’ trial protocol.doc.
Completed SPIRIT checklist. (DOC 121 kb)
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